Synthesis and Pharmacological Characterization of C4<sub>β</sub>-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1<i>S,</i>2<i>S,</i>4<i>S,</i>5<i>R,</i>6<i>S</i>)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu<sub>3</sub> Receptor Agonist
作者:James A. Monn、Steven S. Henry、Steven M. Massey、David K. Clawson、Qi Chen、Benjamin A. Diseroad、Rajni M. Bhardwaj、Shane Atwell、Frances Lu、Jing Wang、Marijane Russell、Beverly A. Heinz、Xu-shan Wang、Joan H. Carter、Brian G. Getman、Kofi Adragni、Lisa M. Broad、Helene E. Sanger、Daniel Ursu、John T. Catlow、Steven Swanson、Bryan G. Johnson、David B. Shaw、David L. McKinzie、Junliang Hao
DOI:10.1021/acs.jmedchem.7b01481
日期:2018.3.22
prepared and evaluated for both mGlu2 and mGlu3 receptor binding affinity and functional cellular responses. From this investigation we identified (1S,2S,4S,5R,6S)-2-amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic acid 8p (LY2794193), a molecule that demonstrates remarkable mGlu3 receptor selectivity. Crystallization of 8p with the amino terminal domain of hmGlu3 revealed critical binding
对于能够选择性活化代谢型谷氨酸3(mGlu 3)受体的化合物,已经提出了多种治疗机会,但是缺少小分子工具。作为我们不断努力发现有效的,选择性,和全身性生物利用激动剂组mGlu的部分2和组mGlu 3受体亚型,一系列C4的β(1 -N-连接变体小号,2小号,5 - [R,6小号) -制备了2-氨基-双环[3.1.0]己烷-2,6-二羧酸1(LY354740),并对其mGlu 2和mGlu 3进行了评估。受体结合亲和力和功能性细胞反应。通过这项研究,我们确定了(1 S,2 S,4 S,5 R,6 S)-2-氨基-4-[(3-甲氧基苯甲酰基)氨基]双环[3.1.0]己烷-2,6-二羧酸8p(LY2794193),一种分子,具有出色的mGlu 3受体选择性。具有hmGlu 3氨基末端结构域的8p的结晶揭示了该配体与邻近谷氨酸结合位点的残基的关键结合相互作用,而8p的药代动力学评估及其在mGlu 2